You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,410,102

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,410,102 protect, and when does it expire?

Patent 8,410,102 protects MIRVASO and is included in one NDA.

This patent has eighty-seven patent family members in twenty-five countries.

Summary for Patent: 8,410,102

Patent landscape, scope, and claims:

Title:	Methods and compositions for treating or preventing erythema
Abstract:	Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one .alpha.-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Dejovin; Jack A. (New Brunswick, NJ), Dejovin; Isabelle Jean (New Brunswick, NJ), Liu; Yin-Sang (Princeton Junction, NJ), Leoni; Matthew James (Hampton, NJ)
Assignee:	Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:	13/072,104
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,410,102
Patent Claim Types: see list of patent claims	Use; Composition;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,410,102

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,410,102

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1631293	⤷ Subscribe	CR 2014 00031	Denmark	⤷ Subscribe
European Patent Office	1631293	⤷ Subscribe	C300683	Netherlands	⤷ Subscribe
European Patent Office	1631293	⤷ Subscribe	1490049-2	Sweden	⤷ Subscribe
European Patent Office	1631293	⤷ Subscribe	C20140022 00150	Estonia	⤷ Subscribe
European Patent Office	1631293	⤷ Subscribe	92462	Luxembourg	⤷ Subscribe
European Patent Office	1631293	⤷ Subscribe	191 5019-2014	Slovakia	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.